Showing results (51-60 of 82) with videos related to
Sort By:
Pageof 9
Journal of Parkinson'S Disease|September 6, 2021
Efficacy of Istradefylline, an Adenosine A2A Receptor Antagonist, as Adjunctive Therapy to Levodopa in Parkinson's Disease: A Pooled Analysis of 8 Phase 2b/3 TrialsRobert A Hauser, Nobutaka Hattori, Hubert Fernandez, et al.Clinical Parkinsonism & Related Disorders|December 10, 2021
AbobotulinumtoxinA provides flexibility for the treatment of cervical dystonia with 500 U/1 mL and 500 U/2 mL dilutionsMark F Lew, Robert A Hauser, Stuart H Isaacson, et al.Clinical Parkinsonism & Related Disorders|March 25, 2022
Efficacy and safety of two incobotulinumtoxinA injection intervals in cervical dystonia patients with inadequate benefit from standard injection intervals of botulinum toxin: Phase 4, open-label, randomized, noninferiority studyCynthia Comella, Robert A Hauser, Stuart H Isaacson, et al.Parkinsonism & Related Disorders|May 2, 2021
Efficacy results of pimavanserin from a multi-center, open-label extension study in Parkinson's disease psychosis patientsStuart H Isaacson, Clive G Ballard, David L Kreitzman, et al.Neurology and Therapy|February 22, 2022
Patterns of Daily Motor-Symptom Control with Carbidopa/Levodopa Enteral Suspension Versus Oral Carbidopa/Levodopa Therapy in Advanced Parkinson's Disease: Clinical Trial Post Hoc AnalysesRajesh Pahwa, Jason Aldred, Niodita Gupta, et al.Journal of Parkinson'S Disease|February 20, 2025
Continuous, subcutaneous apomorphine infusion for Parkinson disease motor fluctuations: Results from the phase 3, long-term, open-label United States InfusON studyStuart H Isaacson, Alberto J Espay, Rajesh Pahwa, et al.JAMA Neurology|June 13, 2017
ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical TrialRajesh Pahwa, Caroline M Tanner, Robert A Hauser, et al.Clinical Parkinsonism & Related Disorders|January 3, 2023
Long-term results of carbidopa/levodopa enteral suspension across the day in advanced Parkinson's disease: Post-hoc analyses from a large 54-week trialRajesh Pahwa, Jason Aldred, Aristide Merola, et al.Parkinsonism & Related Disorders|April 6, 2019
Effect of using a wearable device on clinical decision-making and motor symptoms in patients with Parkinson's disease starting transdermal rotigotine patch: A pilot studyStuart H Isaacson, Babak Boroojerdi, Olga Waln, et al.Movement Disorders Clinical Practice|July 30, 2025
Efficacy and Safety of Foslevodopa/Foscarbidopa Monotherapy in Patients with Parkinson's DiseaseJason Aldred, Manon Bouchard, Juan Carlos Martínez-Castrillo, et al.Pageof 9